Vivani Medical SEC Filings

Vivani Medical, Inc. announced on September 4, 2025 that it has outlined clinical development plans for NPM-139, its investigational semaglutide implant intended for chronic weight management in patients who are obese or overweight with a related comorbidity. The disclosure is furnished as an exhibit (Press Release, Exhibit 99.1) to this Current Report and does not include financial metrics, timelines, enrollment targets, regulatory milestones, or expected costs. The filing is signed by Donald Dwyer, Chief Business Officer.

Vivani Medical reported a widening net loss of $13.4 million for the six months ended June 30, 2025 versus $11.4 million a year earlier, driven by higher R&D and general and administrative expenses. Cash and cash equivalents declined to $6.8 million at June 30, 2025 from $18.4 million at December 31, 2024, total assets fell to $28.9 million from $41.6 million, and stockholders' equity decreased to $4.9 million.

The company progressed its NanoPortal GLP-1 implant programs: the LIBERATE-1 first-in-human trial achieved full enrollment and the first implant administration with positive safety, tolerability and encouraging performance signals, prompting prioritization of NPM-139 (semaglutide implant) toward clinical development. Vivani also filed to spin off Cortigent and secured $21.25 million of committed equity purchase agreements beginning September 2025, and believes currently available cash will fund planned obligations for at least the next twelve months.

Vivani Medical entered a Share Purchase Agreement effective August 11, 2025 to sell 7,936,507 shares of common stock at $1.26 per share, the last reported sale price on that date. The placement is expected to generate approximately $10.0 million in gross proceeds to the Company, with issuances occurring over multiple closings through July 15, 2026, each subject to closing conditions.

The Company stated that no warrants or discounts were provided and that no placement agent or investment banking fees were incurred. The Shares will be issued in reliance on exemptions under Section 4(a)(2) and Rule 506 of Regulation D and have not been registered for resale. The filing attaches a Share Purchase Agreement and a press release and corporate slide presentation as exhibits.

Form 4 Filing Details: Aaron Mendelsohn, Director of Vivani Medical (VANI), received a non-qualified stock option grant on June 24, 2025, as part of the company's Non-Employee Director Compensation Policy.

Key Transaction Details:

• Granted 35,135 stock options to purchase common stock
• Exercise price set at $1.27 per share
• Options expire on June 23, 2035
• Vesting occurs on earlier of: first grant anniversary or next annual stockholder meeting

The filing was signed by Adam Mendelsohn as attorney-in-fact on June 26, 2025. This transaction represents standard annual director compensation and indicates continued board engagement. The vesting structure aligns with typical corporate governance practices for director equity compensation.

Vivani Medical (VANI) reported insider trading activity through a Form 4 filing for Director and 10% Owner Gregg Williams. The filing details two significant option-related transactions:

• On June 24, 2025, Williams was granted 35,135 non-qualified stock options with an exercise price of $1.27. These options vest fully on either the first anniversary or next annual stockholder meeting, whichever comes first.
• A correction was made to a previous January 1, 2025 option grant, adjusting the total beneficial ownership from 76,757 to 76,393 options (exercise price $1.16) due to a clerical error. These options vest quarterly.

The transactions reflect standard director compensation practices and demonstrate continued insider equity participation in the company. The filing was signed by Adam Mendelsohn as attorney-in-fact on June 26, 2025.

Vivani Medical Director Wilford Dean Baker received a non-qualified stock option grant on June 24, 2025, as part of the company's Non-Employee Director Compensation Policy. The grant details include:

• 35,135 options to purchase common stock
• Exercise price of $1.27 per share
• Expiration date of June 23, 2035
• Vesting occurs in full on either the first grant anniversary or next annual stockholder meeting, whichever comes first

The Form 4 filing, signed by Attorney-in-fact Adam Mendelsohn on June 26, 2025, represents a standard annual director compensation grant. The vesting is contingent on Baker's continued service through the vesting date. This equity compensation aligns the director's interests with those of shareholders through long-term stock ownership potential.